INFLAMOSTAT
DEAD

Serial Number

98436739

Owner

3Helix Inc.

Attorney

Constance B. Stefanou

Filing Date

Mar 6, 2024

Add to watchlist:

No watchlists yet
View on USPTO

INFLAMOSTAT Trademark

Serial Number: 98436739

INFLAMOSTAT is a trademark filed by 3Helix Inc. on March 6, 2024. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

3Helix Inc. (2 trademarks)

675 Arapeen Drive, Suite 302
Salt Lake City, UT 84108

Entity Type: 03

Trademark Details

Filing Date

March 6, 2024

Registration Date

Not Registered

Published for Opposition

December 31, 2024

Goods & Services

Synthetic and collagen peptides for use in the fields of medical diagnostics and biotechnology, namely, for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations for use in the fields of medical diagnostics and biotechnology, namely, topical drugs for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for pharmaceutical purposes for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for the treatment of various conditions and diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides sold as ingredient in pharmaceutical preparations for the treatment immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations containing synthetic and collagen peptides for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; chemical preparations for sanitary use, namely, for coating medical devices, and for wound dressings; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; injectable pharmaceuticals for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases;

Cosmetics; ingredient complex composed of synthetic and collagen peptides sold as an integral component of cosmetic preparations;

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 30, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 30, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 27, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 27, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 25, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 31, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 31, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 9, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 9, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 9, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 9, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 9, 2024 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 21, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 19, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 18, 2024 NWOS
NEW APPLICATION ENTERED
Mar 6, 2024 NWAP